Trial Profile
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Bortezomib; Bortezomib; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms CLARION
- Sponsors Amgen; Onyx Pharmaceuticals
- 28 Feb 2019 Results published in the Blood
- 09 Jun 2017 This trial has been completed in Germany (end date: 2016-11-04), according to European Clinical Trials Database record.
- 01 Mar 2017 Data will be presented at at the 16th International Myeloma Workshop (IMW), according to an Amgen media release.